Latest News about BIIB
Recent news which mentions BIIB
From Benzinga
From Benzinga
7 Blue-Chip Stocks Sitting in the Sweet Spot
March 23, 2023
From InvestorPlace
FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder
March 23, 2023
From Benzinga
iMetabolic BioPharma's Alzheimer's Disease Therapeutic Innovation Is A Breakthrough Three-Pronged Approach
March 22, 2023
Tickers
BIIB
From Benzinga
Tickers
BIIB
From MarketWatch
From InvestorPlace
Wall Street predicts approval for another ALS drug
March 21, 2023
From MarketWatch
Despite Failed Phase 3 Study, FDA Staff Says Biogen's ALS Drug May Have Clinical Benefit
March 21, 2023
Tickers
BIIB
From Benzinga
From Benzinga
Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year
March 16, 2023
From Benzinga
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
March 16, 2023
From Benzinga
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
March 14, 2023
From Benzinga
Analyst Creates Bullish Pitch For Sage Therapeutics Around Greater Enthusiasm For Its Depression Drug, Zuranolone
March 13, 2023
From Benzinga
Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock
March 09, 2023
From InvestorPlace
Why Shares of Anavex Life Sciences Rose 12.4% in February
March 06, 2023
From Motley Fool
From Benzinga
From MarketWatch
FDA approves Reata’s rare disease drug amid questions about changes to the regulatory environment for neuroscience treatments
February 28, 2023
From MarketWatch
Why Reata Pharmaceuticals Shares Are Falling Monday?
February 27, 2023
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.